Literature DB >> 1183773

Restoration of antibody-forming capacities by PS-K in tumor-bearing mice.

K Nomoto, C Yoshikumi, K Matsunaga, T Fujii, K Takeya.   

Abstract

PS-K, a protein-bound polysaccharide from a basidiomycetes, was found to suppress tumor growth after grafting of sarcoma-180 or Ehrlich tumor in ICR mice. In the present study, effect of PS-K on antibody-forming capacities was examined in tumor-bearing mice and normal controls. 1) PS-K did not enhance the capacities of normal mice to produce antibodies against sheep erythrocytes (SRBC), hamster erythrocytes (HRBC), and trinitrophenyl group (TNP). 2) The capacities of mice to produce IgG antibody against SRBC, IgM antibody aganist HRBC, and IgG antibody against TNP were depressed after grafting of sarcoma-180. Intraperitoneal injection of PS-K restored these capacities to the normal levels. 3) Oral as well as intraperitoneal administration of PS-K restored the capacity of the mice bearing sarcoma-180 to produce IgG antibody against SRBC. 4) The capacity to produce IgG antibody against SRBC was depressed after grafting of Ehrlick tumor and it recovered to the normal level after intraperitoneal injection of PS-K. These results showed that antibody-fforming capacity of mice was depressed after tumor grafing and recovered after administration of PS-K.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1183773

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  18 in total

1.  Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer.

Authors:  M Torisu; Y Hayashi; T Ishimitsu; T Fujimura; K Iwasaki; M Katano; H Yamamoto; Y Kimura; M Takesue; M Kondo
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK.

Authors:  S Tsuru; K Nomoto; M Taniguchi; H Fujisawa; Y Zinnaka
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Postoperative long term chemotherapy for advanced gastric cancer.

Authors:  N Kaibara; K Soejima; T Nakamura; K Inokuchi
Journal:  Jpn J Surg       Date:  1976-06

4.  A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation.

Authors:  R Ohno; K Yamada; T Masaoka; T Ohshima; I Amaki; Y Hirota; N Horikoshi; A Horiuchi; K Imai; I Kimura
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Influence of PSK (Krestin) on resistance to infection of Pseudomonas aeruginosa in tumor-bearing mice.

Authors:  T Ando; I Motokawa; K Sakurai; Y Ohmura; T Fujii; K Matsunaga; C Yoshikumi; K Nomoto
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Post-operative long-term adjuvant immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients.

Authors:  T Hattori; M Niimoto; T Koh; A Nakano; M Oride; W Takiyama; K Nishimawari
Journal:  Jpn J Surg       Date:  1979-06

7.  The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites.

Authors:  M Hosokawa; T Mizukoshi; K Morikawa; Z Y Xu; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Potentiation of T cell immunity against radiation-leukemia-virus-induced lymphoma by polysaccharide K.

Authors:  E Yefenof; E Einat; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Preoperative serum immunosuppressive acidic protein (IAP) test for the prognosis of gastric cancer: a statistical study of the threshold level and evaluation of the effect of the biological response modifier PSK.

Authors:  J Sakamoto; A Koike; S Saji; S Teramukai; Y Ohashi; H Nakazato
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

10.  Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma.

Authors:  D D Mickey
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.